IMMUNEONCO BIOPHARMACEUTICALS (SHAN financial statements, including revenue, expenses, profit, and loss

The total revenue of 1541 for the last semiannual is 83.44 k HKD, and it's 74.26% lower compared to the previous semiannual. The net income of H1 24 is -179.62 M HKD.